MX2014013049A - Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante. - Google Patents

Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.

Info

Publication number
MX2014013049A
MX2014013049A MX2014013049A MX2014013049A MX2014013049A MX 2014013049 A MX2014013049 A MX 2014013049A MX 2014013049 A MX2014013049 A MX 2014013049A MX 2014013049 A MX2014013049 A MX 2014013049A MX 2014013049 A MX2014013049 A MX 2014013049A
Authority
MX
Mexico
Prior art keywords
transplant rejection
heparan sulfate
biomarker
compositions
methods
Prior art date
Application number
MX2014013049A
Other languages
English (en)
Inventor
Todd V Brennan
Yiping Yang
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MX2014013049A publication Critical patent/MX2014013049A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02007—Heparin lyase (4.2.2.7), i.e. heparinase I
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona métodos para identificar rechazo de trasplante a través del uso de sulfato de heparan como un biomarcador. El método también comprende tratar y/o evitar rechazo de trasplante en un sujeto que comprende administrar al sujeto un inhibidor de sulfato de heparan, por lo mismo tratando y/o evitando el desarrollo de daño mediado por inmunidad después del trasplante.
MX2014013049A 2012-05-01 2013-05-01 Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante. MX2014013049A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641043P 2012-05-01 2012-05-01
US201261660914P 2012-06-18 2012-06-18
PCT/US2013/039086 WO2013166163A1 (en) 2012-05-01 2013-05-01 Compositions and methods for heparan sulfate as a biomarker for transplant rejection

Publications (1)

Publication Number Publication Date
MX2014013049A true MX2014013049A (es) 2015-03-19

Family

ID=49514856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013049A MX2014013049A (es) 2012-05-01 2013-05-01 Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.

Country Status (7)

Country Link
US (1) US20160109459A1 (es)
EP (1) EP2844278A4 (es)
JP (1) JP2015517469A (es)
BR (1) BR112014027333A2 (es)
CA (1) CA2872104A1 (es)
MX (1) MX2014013049A (es)
WO (1) WO2013166163A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
WO2017123549A1 (en) * 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids
WO2019129824A1 (en) * 2017-12-27 2019-07-04 Vito Nv Biomarkers for typing allograft recipients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512090B2 (en) * 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Treatment of inflammation
ES2516690T5 (es) * 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
WO2008046162A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
EP2550004A4 (en) * 2010-03-12 2014-07-02 Univ Australian SUBSTITUTE THERAPY WITH HEPARAN SULFATE

Also Published As

Publication number Publication date
JP2015517469A (ja) 2015-06-22
EP2844278A4 (en) 2015-11-04
WO2013166163A1 (en) 2013-11-07
US20160109459A1 (en) 2016-04-21
CA2872104A1 (en) 2013-11-07
BR112014027333A2 (pt) 2017-07-18
EP2844278A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
IN2015DN02634A (es)
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
IN2015DN00438A (es)
MX2012008360A (es) Antidotos de anticoagulantes.
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX354270B (es) Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
GB201109238D0 (en) Antibodies
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
MX2021000332A (es) Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
TN2013000388A1 (en) Anticoagulant antidotes
UA112132C2 (uk) Обробка розчинної кави
NZ628433A (en) Chitosan-derived compositions
MX2014003223A (es) Composiciones y metodos para tratar el cancer usando el inhibidor de pi3kbeta y el inhibidor de la via de mapk, incluidos los inhibidores de mek y raf.
IN2014KN02914A (es)
IN2014DN08385A (es)
MX338994B (es) Composiciones de poliolefinas autoemulsionantes.
MX2014013049A (es) Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.